Emtricitabine/tenofovir-disoproxil-fumarate

Abstract

Dyslipidaemia: case report A 51-year-old man developed dyslipidaemia during treatment with emtricitabine/tenofovir-disoproxil-fumarate for HIV preexposure prophylaxis. The man, who had history of hypertension, hyperlipidemia and hypothyroidism, presented with typical and crescendo angina over the week. He had been receiving HIV pre-exposure prophylaxis treatment with emtricitabine/tenofovir-disoproxil-fumarate [Emtricitabine-Tenofovir; route and dosage not stated]. Thereafter, he had also bee receiving rosuvastatin along with fish oil for hyperlipidemia. Subsequently, his EKG revealed biphasic T wave inversions in V1-V3 and deep symmetrical T-wave inversions in V4-V6, suggestive of Wellen’s syndrome. Echocardiogram showed an ejection fraction of 55% with left ventricular hypertrophy, mid-ventricular anterior wall hypokinesis and apical akinesis. Thereafter, his laboratory report showed high-sensitivity troponin was 79 ng/dL, total cholesterol of 168, triglycerides of 126, and low and high-density lipoproteins were 99 and 44, respectively. He was diagnosed with non-ST segment elevation myocardial infarction (NSTEMI) secondary to dyslipidaemia. Therefore, the man was treated with heparin drip. He also underwent everolimus drug-eluting stent placement. He had a diffusely mild disease during his left circumflex artery and right coronary artery. Following the procedure, his repeated EKG showed persistent anterolateral T-wave inversion. Then, his lipoprotein(a) was 97 mg/dL.